Login / Signup

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Zoe JohnsonChiara TarantelliElisa CivanelliLuciano CascioneFilippo SprianoAmy FraserPritom ShahTyzoon NomanbhoySara NapoliAndrea RinaldiKarolina Niewola-StaszkowskaMichael LahnDominique PerrinMathias WenesDenis MiglioriniFrancesco BertoniLars van der VeenGiusy Di Conza
Published in: Cancer research communications (2023)
antitumor activity in various models with limited toxicity in animal studies provides the rationale for the ongoing trials in patients with solid tumors and hematologic cancers.
Keyphrases
  • case control
  • oxidative stress
  • clinical trial
  • oxide nanoparticles